SARS-CoV-2 RBD-Tetanus Toxoid Conjugate Vaccine Induces a Strong Neutralizing Immunity in Preclinical Studies.

  title={SARS-CoV-2 RBD-Tetanus Toxoid Conjugate Vaccine Induces a Strong Neutralizing Immunity in Preclinical Studies.},
  author={Yury Vald{\'e}s-Balb{\'i}n and Darielys Santana-Mederos and Lauren Quintero and Sonsire Fernandez and Laura Rodriguez and Belinda S{\'a}nchez Ram{\'i}rez and Rocmira Perez-Nicado and Claudia Acosta and Yanira M{\'e}ndez and Manuel G Ricardo and Tays Hern{\'a}ndez and Gretchen Bergado and Franciscary Pi and Annet Valdes and Tania Carmenate and Ubel Ram{\'i}rez and Reinaldo Oliva and Jean Pierre Soubal and Raine Garrido and Félix Cardoso and Mario Landys and Humberto Gonz{\'a}lez and Mildrey Fari{\~n}as and Juliet Enriquez and Enrique Noa and Anamary Suarez and Cheng Fang and Luis Ariel Espinosa and Yassel Ramos and Luis Javier Gonz{\'a}lez and Yanet Climent and Gertrudis Rojas and Ernesto Relova-Hern{\'a}ndez and Yanelys Cabrera Infante and Sum Lai Losada and Tammy Boggiano and Eduardo Ojito and Kalet Leon and Fabrizio Chiodo and Françoise Paquet and Guang-Wu Chen and Daniel G. Rivera and Dagmar Garc{\'i}a-Rivera and Vicente Verez Bencomo},
  journal={ACS chemical biology},
Controlling the global COVID-19 pandemic depends, among other measures, on developing preventive vaccines at an unprecedented pace. Vaccines approved for use and those in development intend to elicit neutralizing antibodies to block viral sites binding to the host's cellular receptors. Virus infection is mediated by the spike glycoprotein trimer on the virion surface via its receptor binding domain (RBD). Antibody response to this domain is an important outcome of immunization and correlates… 

A New iNKT-Cell Agonist-Adjuvanted SARS-CoV-2 Subunit Vaccine Elicits Robust Neutralizing Antibody Responses.

It is found that a new iNKT-cell agonist αGC-CPOEt elicited a strong cytokine response with increased IL-4 production, implying that α GC- CPOEt could be investigated further as a new COVID-19 vaccine adjuvant to prevent current and future infectious disease outbreaks.

Immune Evasive Effects of SARS-CoV-2 Variants to COVID-19 Emergency Used Vaccines

The prevalence and biological structure of these variants and the efficacy of currently used vaccines against the SARS-CoV-2 variants are summarized to provide guidance on how to design vaccines more rationally against the variants.

A Novel Bacterial Protease Inhibitor Adjuvant in RBD-Based COVID-19 Vaccine Formulations Containing Alum Increases Neutralizing Antibodies, Specific Germinal Center B Cells and Confers Protection Against SARS-CoV-2 Infection in Mice

Results show that the vaccine formulation composed of U-Omp19 and alum as adjuvants has a better performance: it significantly increased mucosal and systemic neutralizing antibodies in comparison to antigen plus alum, AddaVax, or AddaS03.

Structure Guided Design of Bacteriophage Qβ Mutants as Next Generation Carriers for Conjugate Vaccines.

Novel mutants of bacteriophage Qβ (mQβ) have been designed, which upon conjugation with tumor associated carbohydrate antigens (TACAs) elicited powerful anti-TACA IgG responses and yet produced lower levels of anticarrier antibodies as compared to those from the wild type Qβ-T ACA conjugates.

Combined Subcutaneous-Intranasal Immunization With Epitope-Based Antigens Elicits Binding and Neutralizing Antibody Responses in Serum and Mucosae Against PRRSV-2 and SARS-CoV-2

Results show that intranasal immunization, alone or combined with subcutaneous delivery of epitope-based antigens, generates local and systemic binding and neutralizing antibodies.

Evaluation of Safety and Immunogenicity of a Recombinant Receptor-Binding Domain (RBD)-Tetanus Toxoid (TT) Conjugated SARS-CoV-2 Vaccine (PastoCovac) in Recipients of Autologous Hematopoietic Stem Cell Transplantation Compared to the Healthy Controls; A Prospective, Open-Label Clinical Trial

The RBD-TT conjugated SARS-CoV-2 vaccine was safe, highly immunogenic, and affordable early after autologous transplants and it was found that the immunogenicity of the COVID-19 vaccine shortly after transplantation could be influenced by pre-transplant CO VID-19 vaccination.

Recombinant Protein Vaccines against Human Betacoronaviruses: Strategies, Approaches and Progress

The information on the designing of vaccines based on recombinant proteins against highly pathogenic human betacoronaviruses SARS- coV, MERS-CoV and SARS -CoV-2 is summarized.

Safety and immunogenicity of anti-SARS CoV-2 vaccine SOBERANA 02 in homologous or heterologous scheme

SOBERANA 02 was safe and immunogenic in persons aged 19–80 years, eliciting neutralizing antibodies and specific T cell response and it was higher after both the homologous and heterologous third doses; theheterologous scheme showing a higher immunological response.



Molecular Aspects Concerning the Use of the SARS-CoV-2 Receptor Binding Domain as a Target for Preventive Vaccines

This review summarizes with a critical view the molecular aspects associated with the interaction of SARS-CoV-2 RBD with its receptor in human cells, the angiotensin-converting enzyme 2 (ACE2), the epitopes involved in the neutralizing activity, and the impact of virus mutations thereof.

Isolation of potent SARS-CoV-2 neutralizing antibodies and protection from disease in a small animal model

A role for potent neutralizing antibodies (nAbs) in prophylaxis, and potentially therapy, of COVID-19 is suggested, as indicated by maintained weight and low lung viral titers in treated animals, and the passive transfer of a nAb provides protection against disease in high-dose SARS-CoV-2 challenge in Syrian hamsters.

Structural basis of a shared antibody response to SARS-CoV-2

It is found that immunoglobulin G heavy-chain variable region 3-53 (IGHV3-53) is the most frequently used IGHV gene for targeting the receptor-binding domain (RBD) of the spike protein, which is promising for vaccine design.

A COVID-19 vaccine candidate using SpyCatcher multimerization of the SARS-CoV-2 spike protein receptor-binding domain induces potent neutralising antibody responses

The induction of potent and polyclonal antibody responses by RBD-SpyVLP provides strong potential to address clinical and logistic challenges of the COVID-19 pandemic.

Capsid-like particles decorated with the SARS-CoV-2 receptor-binding domain elicit strong virus neutralization activity

The authors generate a capsid-like particle based vaccine candidate displaying the receptor-binding domain of the SARS-CoV-2 spike protein and show induction of neutralizing antibodies after intramuscular prime-boost immunization in mice.

A SARS-CoV-2 surrogate virus neutralization test based on antibody-mediated blockage of ACE2–spike protein–protein interaction

A blocking assay based on the recombinant receptor-binding domain of SARS-CoV-2 spike protein and human angiotensin-converting enzyme 2 receptor provides an alternative to conventional antibody neutralization assays requiring live virus.

Potently neutralizing and protective human antibodies against SARS-CoV-2

An analysis identifies human monoclonal antibodies that potently neutralize wild-type SARS-CoV-2 and protect animals from disease, including two that synergize in a cocktail, suggesting that these could be candidates for use as therapeutic agents for the treatment of COVID-19 in humans.

Is smaller better? Vaccine targeting recombinant receptor-binding domain might hold the key for mass production of effective prophylactics to fight the COVID-19 pandemic

The study highlights the critical role of the immunogenicity of the RBD domain upon SARS-CoV-2 infection and the alternate vaccine designs that could serve as effective prophylactics against the pandemic.